Pramlintide challenge blood test (DTAD)
Develop a simple blood-based test for early detection of Alzheimer's disease (AD) based on a single injection of Pramlintide. The measured difference in the level of plasma Aß taken just before and a short time after injection of Pramlintide should reveal the magnitude of the transient increase in blood Aß levels correlated with cognitive impairments.
three groups of participants will be studied: 1) amnestic MCI with or without positive AD imaging pathology, 2) probable AD with positive imaging AD pathology, and 3) controls who have normal cognition and do not have memory complaints.
240
blood draw, mild discomfort, in clinic visits
phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, western blot, or qPCR)
Boston University
“Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease (DTAD).”Accessed October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT03560960?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=6&rank=59